Health
Australia set to host clinical trial of genetically modified Covid nasal spray vaccine – The Guardian
Australian company applies for permission to conduct trial of men and women aged 18 to 55
Vaccines and immunisationAustralian company applies for permission to conduct trial of men and women aged 18 to 55
Australia is set to host the first human clinical trial of a genetically modified adenovirus vaccine for Covid-19 delivered via nasal spray.
Avance Clinical, an Australian contract research organisation, has applied to the office of the gene technology regulator for permission to conduct the phase 1 clinical trial on behalf US company Tetherex Pharmaceuticals Corporation.
The trial…
-
Noosa News24 hours agoMan dies after stabbing in inner-city unit
-
General22 hours agoTwo British MPs refused entry into Israel, UK foreign ministry says
-
Noosa News22 hours agoBrisbane man, 39, dies after stabbing at inner city home in early morning attack, prompting investigation
-
General16 hours agoChinese spies, ports and Donald | Scam of the Week